"Network Medicine and Drug Repurposing Network Medicine and Drug Repurposing" Prof. Joseph Loscalzo, MD, PhD (Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts)

Conventional drug discovery requires identifying a protein target believed to be important for disease mechanism and screening compounds for those that beneficially alter the target’s function. While this approach has been an effective one for decades, recent data suggest that its continued success is limited largely owing to the essential irreducibility of biologically complex systems that govern disease phenotype to a single primary disease driver. Moreover, bioinformatic analysis suggests that each approved drug can theoretically bind to ~32 targets, supporting the notion that many existing drugs can be repurposed for the treatment of (many) other diseases. Network medicine, a new discipline that applies network science and systems biology to the analysis of complex biological systems and disease, offers a novel approach to overcoming these limitations of conventional drug discovery, and dissecting the complexity implicit in the pluripotency of many drug compounds. Using the comprehensive protein-protein interaction network (interactome) as the template through which subnetworks that govern specific diseases are identified; potential disease drivers are unveiled; and the effect of repurposed drugs, identified from network features, physicochemical compound features, and machine learning- and artificial intelligence-based analyses, are studied. This approach to drug discovery offers new and exciting unbiased possibilities for advancing our knowledge of disease mechanisms and precision therapeutics.


27 ottobre 2022, alle ore 11.00, Aula A del

Dipartimento di Chimica e tecnologie del farmaco (Edificio CU019)

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma